Bile Acids Turn Cells from Fat-storing to Fat-burning
Obesity arises from an imbalance between energy intake and energy expenditure. As a result, current treatments try to decrease calorie intake and/or increase energy expenditure.
The problem is maintaining long-term effects. Non-invasive treatments, like diets and drugs that reduce intestinal ingestion are widely unpopular among patients, while bariatric surgery seems to be the only reliable treatment for obese people, despite being both expensive and invasive.
But now a new study led by the lab Kristina Schoonjans at EPFL, suggests that a specific group of bile acids could directly burn away the lipids in our fat depots, effectively making it a new therapy against obesity.
Bile acids are important constituents of bile, a yellow-green fluid produced in the liver that is stored in the gallbladder and secreted into the intestines during a meal. Bile emulsifies dietary fat into tiny globules that can be broken down by digestive enzymes to be absorbed by the intestine.
The EPFL scientists discovered that bile acids can turn fat-storing cells into fat-burning ones. This process is called thermogenesis (literally, “heat production”) and it helps maintain body temperature in cold environments.
There are three different types of fat cells: white fat cells, which store energy; brown fat cells, which expend energy; and the so-called “beige” fat cells, which are functionally related to brown cells while being located in typically white-fat depots.
Beige cells have recently attracted a lot of attention, especially because adults have very low numbers of active brown adipocytes that burn energy. But what can turn a white cell into a beige one – a process called "beiging" – and shift the balance from fat-storing to fat-burning?
The work of Schoonjans’ team suggests that this process can be coordinated by secondary bile acids, metabolites that are generated by our liver and gut bacteria.
The study shows that activating the bile acid receptor TGR5 with molecules that mimic the action of bile acids (so called "mimetics") induces a remodeling of white fat cells into beige fat cells. The bile acids accumulate in the blood and interact with the TGR5 receptor on white fat cells to change their metabolic function.
This is more than a mere change of color, as the researchers also found that these bile acids increase the number of mitochondria in the new fat cells. This indicates higher energy consumption in the new, beige fat cells.
The bile-acid mimetics also triggered lipolysis, the first step in fat degradation, allowing the fat cells to use fatty acids as their main fuel source.
The study provides a direct connection between bile acids and fat loss and envisions novel therapeutic intervention in obese people. “We showed that bile acids are much more than a soap for digestion,” says Kristina Schoonjans. “When their concentration in the blood reaches a certain level, it can turn up the thermostat and increase fat burning for energy and heat production”.
“What is exciting about our discovery is that low concentrations of TGR5-selective molecules are sufficient to promote the beiging of white fat-storing cells, thereby bypassing the need to increase the total bile acid pool," says Laura Velazquez, first-author of the paper.
“Moreover, this study highlights mitochondrial fission —or the splitting of mitochondria— as a pivotal mechanism by which bile acids turn white fat into beige fat," adds Alessia Perino, co-first author. "It will be interesting to explore if mitochondrial fission is a universal mechanism for beiging in response to other stimuli”.
This article has been republished from materials provided by EPFL. Note: material may have been edited for length and content. For further information, please contact the cited source.
Velazquez-Villegas, L. A., Perino, A., Lemos, V., Zietak, M., Nomura, M., Pols, T. W., & Schoonjans, K. (2018). TGR5 signalling promotes mitochondrial fission and beige remodelling of white adipose tissue. Nature Communications, 9(1). doi:10.1038/s41467-017-02068-0
Calidi Biotherapeutics, Inc. Announces its Corporate Vision in Groundbreaking Cancer Drug DevelopmentNews
Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE